Care that knows when losartan is the right move, not just a refill.
Losartan is the ARB of choice when an ACE inhibitor is intolerable. Clara auto-syncs your chart and drafts the plan against every medication, allergy, and lab on record.
Follow-up BMP drafted at 2 to 4 weeks. I'll track whether the cough resolves and flag if potassium trends up.
Losartan chosen from your data, not a template.
Connect your chart
Clara auto-syncs your records from 150,000+ doctors' offices, hospitals, clinics, labs, and wearable devices. Past ACE trials, proteinuria, echo reports showing LVH — it's all pulled in. Free.
Clara reasons across your full context
Clara reads your lab history (potassium, creatinine, urinary albumin), your medication list, and your BP trend, then drafts a starting dose of losartan (typically 50 mg once daily) plus baseline and follow-up labs. A licensed physician reviews and signs off.
Watch for response, not just refills
Clara watches your home BP trend and follow-up BMP, flags potassium drift, and drafts a dose step-up to 100 mg or an add-on agent against your full chart if you're not at goal.
Try Clara before you fill your next losartan refill.
Starting doses, the three on-label indications, and common combinations.
Losartan 50 mg daily
Usual starting dose for adult hypertension, up to 100 mg daily. Lower starting dose (25 mg) when a patient is volume-depleted or on a diuretic1.
Hypertension + LVH
In the LIFE trial (9,193 patients with hypertension and left ventricular hypertrophy), losartan reduced the primary composite of CV death, MI, and stroke by 13% vs. atenolol2.
Type 2 diabetes with proteinuria
Indicated to delay progression of diabetic nephropathy in type 2 diabetes with a history of hypertension1. RENAAL showed a 16% reduction in the composite of doubling of creatinine, ESRD, or death3.
Losartan + HCTZ
Common pairing when monotherapy does not reach goal. Adding low-dose hydrochlorothiazide provides additive BP lowering and offsets ARB-associated potassium elevation.
Basic metabolic panel
Baseline before starting an ARB, then at 2 to 4 weeks and after dose changes. Clara drafts the order as part of the plan. Ad-hoc lab orders at Labcorp or Quest may be covered by your insurance.
Sodium, DASH, weight
Clara layers DASH-style eating, reduced sodium, and weight trend against your home BP readings and wearable resting heart rate, for additive BP lowering on top of the ARB.
An ARB is not interchangeable with an ACE inhibitor. The AI should know the difference.
| Clara | GoodRx Care | Circle Medical | Your doctor | |
|---|---|---|---|---|
| 24/7 AI clinical chat with full-chart reasoning | Unlimited | Per-visit only | Visit-based | ✗ |
| Automated switch from ACE to ARB on reported cough | Drafted instantly | New visit required | New visit | Next appointment |
| Cost to start | Free (connect records + chat) | $49 per hypertension refill visit | $179 first visit self-pay | $150+ copay |
| Paid plans | $25/mo membership, HSA/FSA eligible | No membership, $49/visit ($19 w/ GoodRx Gold) | No membership, $120 follow-up self-pay | Per-visit copay |
| Prescription fills | FDA-approved generic, may be covered by your insurance | Sent to your pharmacy | Sent to your pharmacy | Sent to your pharmacy |
| Follow-up BMP (K, Cr) included | Drafted automatically | Separate visit | Ordered at visit | Copay applies |
| Full primary care in one membership | Single-visit refill |
GoodRx Care writes the refill. Clara reads the echo, the eGFR, and the trials that apply to you.
Clara reads every trial that applies to your chart.
Can your old doctor recite the LIFE-trial hazard ratio, the RENAAL endpoint, and the exact losartan dosing algorithm next to your echo report and your most recent eGFR in 15 minutes? Clara can, every time.
Cross-references your chart against the literature
If your chart shows LVH on echo or microalbuminuria with type 2 diabetes, Clara flags that losartan is on-label for stroke-risk reduction and diabetic nephropathy and pulls the supporting trial directly into the reasoning.
ACE-to-ARB switch, without a new visit
Dry cough on an ACE inhibitor does not need to wait for your next appointment. Clara drafts the switch in seconds with your potassium, creatinine, and BP trend in hand.
Potassium, watched continuously
ARBs raise potassium. Clara auto-reads your next BMP and flags any creep toward 5.5 mmol/L, catches NSAID or potassium-sparing-diuretic additions, and drafts a plan before you feel it.
Care that reads every BMP and every home BP reading against your full chart.
Common questions
Losartan questions patients ask.
How is Clara different from a single refill visit?
When is losartan the right choice instead of lisinopril?
Is 50 mg the right starting dose?
Does losartan cause a cough?
Can I take losartan while pregnant?
Is Clara a real medical practice?
What does Clara cost, and can I use insurance?
Can I use Clara for other health issues too?
The AI reads the trial that applies to your chart. The plan is built from your data.
Connect your records, chat with Clara for free, and see whether losartan is the right next move, built from your own data.
Get startedLosartan carries a boxed warning for fetal toxicity: discontinue as soon as pregnancy is detected. Other labeled risks include symptomatic hypotension (especially in volume-depleted patients), acute kidney injury, and hyperkalemia. Cozaar is a registered trademark of Merck Sharp & Dohme LLC.
For important safety information about losartan, see the FDA Medication Guide and prescribing information: Losartan (Cozaar). For mentioned alternatives, see Lisinopril and Hydrochlorothiazide.
1Cozaar (losartan potassium) tablets: FDA-approved prescribing information. Indications sourced from Section 1 (hypertension, hypertensive patients with left ventricular hypertrophy for stroke risk reduction, diabetic nephropathy in type 2 diabetes with a history of hypertension). Dosing from Section 2 (usual starting dose 50 mg once daily in hypertension; 25 mg starting dose in volume-depleted patients). Pregnancy warning from Section 5.1 and boxed warning. View DailyMed label.
2Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003. Primary composite (CV death, MI, stroke) in 9,193 patients with hypertension and LVH: hazard ratio 0.87 (95% CI 0.77–0.98, p=0.021) in favor of losartan; stroke incidence was significantly lower. View on PubMed.
3Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869. RENAAL: losartan reduced the composite of doubling of serum creatinine, end-stage renal disease, or death by 16% (risk ratio 0.84, 95% CI 0.72–0.98, p=0.02) vs. placebo added to conventional therapy. View on PubMed.
4Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. Am J Med. 2010;123(11):1016–1030. ARB cough incidence is substantially lower than ACE-inhibitor cough; the standard clinical response to ACE-inhibitor cough is to switch to an ARB. View on PubMed.